Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.

Expert opinion on drug metabolism & toxicology - 1 Dec 2017

Rossi Antonio, Muscarella Lucia Anna, Di Micco Concetta, Carbonelli Cristiano, D'alessandro Vito, Notarangelo Stefano, Palomba Giuseppe, Sanpaolo Gerardo, Taurchini Marco, Graziano Paolo, Maiello Evaristo

Abstract excerpt

INTRODUCTION: First- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, icotinib, and afatinib are the standard-of-care for first-line therapy of non-small-cell lung cancer (NSCLC) harboring activating EGFR mutations. Unfortunately, after initial activity of an average 9-13 months, disease progression has been reported in the majority of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease Progression

Share to ErbB Receptors

Share to Piperazines

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29095090
DOI: 10.1080/17425255.2017.1401064

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.PMID 29095090Read ↗

The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupSemantic proximity Read ↗

Osimertinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.Semantic proximity Read ↗

Osimertinib making a breakthrough in lung cancer targeted therapySemantic proximity Read ↗

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care.Semantic proximity Read ↗

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.Semantic proximity Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Semantic proximity Read ↗

Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.